风湿证胃癌前病变微观表型特征的探索性研究

注册号:

Registration number:

ChiCTR2600125511 

最近更新日期:

Date of Last Refreshed on:

2026-05-27 16:55:52 

注册时间:

Date of Registration:

2026-05-27 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

风湿证胃癌前病变微观表型特征的探索性研究

Public title:

An Exploratory Study on the Microscopic Phenotypic Characteristics of Fengshi syndrome Precancerous Lesions of Gastric Cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

风湿证胃癌前病变微观表型特征的探索性研究

Scientific title:

An Exploratory Study on the Microscopic Phenotypic Characteristics of Fengshi syndrome Precancerous Lesions of Gastric Cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐嘉敏 

研究负责人:

杨小波 

Applicant:

Jiamin Xu 

Study leader:

Xiaobo Yang 

申请注册联系人电话:

Applicant telephone:

+86 156 2621 8487

研究负责人电话:

Study leader's
telephone:

+86 138 2501 2636

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiaminxu@gzucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

yangxiaobomd@gzucm.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市大德路111号

研究负责人通讯地址:

广东省广州市大德路111号

Applicant address:

111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province, China

Study leader's address:

111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

研究负责人所在单位:

广州中医药大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

广东省中医院伦理委员会ZF2026-031-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-16 00:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8188 7233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@gzucm.edu.cn

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangzhou Provincial Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第二附属医院

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

Guangzhou Provincial Hospital of Chinese Medicine

Address:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

胃癌前病变  

Target disease:

gastric precancerous lesions

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

风湿证胃癌前病变由于其半表半里、黏膜属表等特性,与脏腑风湿理论相契合,是胃癌前病变的特异性证型。本研究拟采集风湿证与非风湿证胃癌前病变患者的胃黏膜组织进行组织微观生物学比较,探索风湿证的微观生物学特征。本研究将阐明风湿证胃癌前病变的病变特征,对风湿证胃癌前病变的药物研发,以及丰富脏腑风湿的微观生物学证据具有重大意义。  

Objectives of Study:

Because of the characteristics of half surface and half interior, mucosa belongs to the surface, which is consistent with the theory of Zangfu rheumatism, it is a specific syndrome type of gastric precancerous lesions. The aim of this study is to compare the microbiology of gastric mucosa tissues between patients with rheumatic and non-rheumatic precancerous lesions, and to explore the microbiological characteristics of rheumatic diseases. This study will clarify the pathological characteristics of gastric precancerous lesions of rheumatic disease, which is of great significance for the drug development of gastric precancerous lesions of rheumatic disease, and enrich the microbiological evidence of zangfu rheumatism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.胃黏膜癌变者; 2.合并恶性肿瘤者; 3.存在其他消化系统疾病者; 4.合并严重心、肺、肝、肾等重要脏器疾病者; 5.妊娠或哺乳期妇女; 6.有影响患者自诉能力严重脑疾病或精神疾病。

Exclusion criteria:

1. Gastric cancer; 2. Combined with malignant tumors; 3. With other digestive diseases; 4. Complicated with serious heart, lung, liver, kidney and other important organ diseases; 5. Pregnant or lactating women; 6. Serious brain disease or mental disease that affects the patient's ability to report.

研究实施时间:

Study execute time:

From 2026-04-16 00:00:00 To 2028-04-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-14 00:00:00 To 2028-04-16 00:00:00

干预措施:

Interventions:

组别:

非风湿证胃癌前病变组

样本量:

8

Group:

Non-Fengshi precancerous lesions group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

风湿证胃癌前病变组

样本量:

8

Group:

Fengshi precancerous lesions group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

临床症状量表评分

指标类型:

主要指标

Outcome:

Clinical Symptom Scale Scoring

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医四诊量表评分

指标类型:

次要指标

Outcome:

Chinese Medicine Four Diagnostic Scale Scoring

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

胃黏膜

组织:

Sample Name:

gastric mucosa

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在本研究主要结果首次正式发表后6个月内,研究者可共享去标识化的个体受试者数据(IPD)、数据字典及研究方案。数据共享方式为按合理请求提供。申请者可通过电子邮件向通讯作者提出申请,经研究团队审核批准并签署数据使用协议后,以加密电子文件方式提供相关数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the first formal publication of the main study results, de-identified individual participant data (IPD), together with the data dictionary and study protocol, will be available upon reasonable request. Researchers may contact the corresponding author by email. After approval by the study team and signing a data use agreement, the requested data will be provided in encrypted electronic files.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-27 16:55:37